261 related articles for article (PubMed ID: 19389522)
1. Minichromosome maintenance proteins are useful adjuncts to differentiate between benign and malignant melanocytic skin lesions.
Gambichler T; Shtern M; Rotterdam S; Bechara FG; Stücker M; Altmeyer P; Kreuter A
J Am Acad Dermatol; 2009 May; 60(5):808-13. PubMed ID: 19389522
[TBL] [Abstract][Full Text] [Related]
2. Protein expression of carcinoembryonic antigen cell adhesion molecules in benign and malignant melanocytic skin lesions.
Gambichler T; Grothe S; Rotterdam S; Altmeyer P; Kreuter A
Am J Clin Pathol; 2009 Jun; 131(6):782-7. PubMed ID: 19461083
[TBL] [Abstract][Full Text] [Related]
3. Versican overexpression in cutaneous malignant melanoma.
Gambichler T; Kreuter A; Grothe S; Altmeyer P; Brockmeyer NH; Rotterdam S
Eur J Med Res; 2008 Nov; 13(11):500-4. PubMed ID: 19073385
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of microtubule-associated protein 2 in melanocytic skin lesions.
Gambichler T; Rotterdam S; Radkowski K; Altmeyer P; Kreuter A
Am J Clin Pathol; 2009 May; 131(5):710-4. PubMed ID: 19369632
[TBL] [Abstract][Full Text] [Related]
5. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
6. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
7. Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression.
Einspahr JG; Thomas TL; Saboda K; Nickolof BJ; Warneke J; Curiel-Lewandrowski C; Ranger-Moore J; Duckett L; Bangert J; Fruehauf JP; Alberts DS
Cancer; 2007 Dec; 110(11):2519-27. PubMed ID: 17932890
[TBL] [Abstract][Full Text] [Related]
8. Loss of claudin-1 expression in tumor-associated vessels correlates with acquisition of metastatic phenotype in melanocytic neoplasms.
Cohn ML; Goncharuk VN; Diwan AH; Zhang PS; Shen SS; Prieto VG
J Cutan Pathol; 2005 Sep; 32(8):533-6. PubMed ID: 16115050
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
10. Replicative MCM7 protein as a proliferation marker in endometrial carcinoma: a tissue microarray and clinicopathological analysis.
Li SS; Xue WC; Khoo US; Ngan HY; Chan KY; Tam IY; Chiu PM; Ip PP; Tam KF; Cheung AN
Histopathology; 2005 Mar; 46(3):307-13. PubMed ID: 15720416
[TBL] [Abstract][Full Text] [Related]
11. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
[TBL] [Abstract][Full Text] [Related]
12. Expression of replication-licensing factors MCM2 and MCM3 in normal, hyperplastic, and carcinomatous endometrium: correlation with expression of Ki-67 and estrogen and progesterone receptors.
Kato K; Toki T; Shimizu M; Shiozawa T; Fujii S; Nikaido T; Konishi I
Int J Gynecol Pathol; 2003 Oct; 22(4):334-40. PubMed ID: 14501812
[TBL] [Abstract][Full Text] [Related]
13. Expression of proliferation markers and cell cycle regulators in T cell lymphoproliferative skin disorders.
Gambichler T; Bischoff S; Bechara FG; Altmeyer P; Kreuter A
J Dermatol Sci; 2008 Feb; 49(2):125-32. PubMed ID: 17826963
[TBL] [Abstract][Full Text] [Related]
14. A subgroup of melanocytic nevi on the distal lower extremity (ankle) shares features of acral nevi, dysplastic nevi, and melanoma in situ: a potential misdiagnosis of melanoma in situ.
Khalifeh I; Taraif S; Reed JA; Lazar AF; Diwan AH; Prieto VG
Am J Surg Pathol; 2007 Jul; 31(7):1130-6. PubMed ID: 17592281
[TBL] [Abstract][Full Text] [Related]
15. Minichromosome maintenance-7 and geminin are reliable prognostic markers in patients with oral squamous cell carcinoma: immunohistochemical study.
Tamura T; Shomori K; Haruki T; Nosaka K; Hamamoto Y; Shiomi T; Ryoke K; Ito H
J Oral Pathol Med; 2010 Apr; 39(4):328-34. PubMed ID: 20136698
[TBL] [Abstract][Full Text] [Related]
16. Minichromosome maintenance protein 3 is a candidate proliferation marker in papillary thyroid carcinoma.
Lee YS; Ha SA; Kim HJ; Shin SM; Kim HK; Kim S; Kang CS; Lee KY; Hong OK; Lee SH; Kwon HS; Cha BY; Kim JW
Exp Mol Pathol; 2010 Feb; 88(1):138-42. PubMed ID: 19818763
[TBL] [Abstract][Full Text] [Related]
17. Expression of cell cycle and apoptosis regulatory proteins and telomerase in melanocitic lesions.
Batinac T; Hadzisejdić I; Brumini G; Ruzić A; Vojniković B; Zamolo G
Coll Antropol; 2007 Jan; 31 Suppl 1():17-22. PubMed ID: 17469743
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression patterns of the microRNA-processing enzyme Dicer in cutaneous malignant melanomas, benign melanocytic nevi and dysplastic melanocytic nevi.
Sand M; Gambichler T; Sand D; Altmeyer P; Stuecker M; Bechara FG
Eur J Dermatol; 2011; 21(1):18-21. PubMed ID: 21262599
[TBL] [Abstract][Full Text] [Related]
19. AgNORs in benign, dysplastic, and malignant melanocytic skin lesions.
Howat AJ; Wright AL; Cotton DW; Reeve S
Am J Dermatopathol; 1990 Apr; 12(2):156-61. PubMed ID: 2331050
[TBL] [Abstract][Full Text] [Related]
20. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma.
Massi D; Naldini A; Ardinghi C; Carraro F; Franchi A; Paglierani M; Tarantini F; Ketabchi S; Cirino G; Hollenberg MD; Geppetti P; Santucci M
Hum Pathol; 2005 Jun; 36(6):676-85. PubMed ID: 16021575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
